This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munz, B.
Right arrow Articles by Blau, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munz, B.
Right arrow Articles by Blau, H. M.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, August 2002, p. 5879-5886, Vol. 22, No. 16
0270-7306/02/$04.00+0     DOI: 10.1128/MCB.22.16.5879-5886.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

RIP2, a Checkpoint in Myogenic Differentiation

Barbara Munz,1 Eberhard Hildt,2 Matthew L. Springer,1 and Helen M. Blau1*

Baxter Laboratory for Genetic Pharmacology, Stanford University Medical Center, Stanford, California 94305-5175,1 Robert Koch Institute, D-13353 Berlin, Germany2

Received 30 July 2001/ Returned for modification 24 October 2001/ Accepted 22 May 2002

Using a subtractive cDNA library hybridization approach, we found that receptor interacting protein 2 (RIP2), a tumor necrosis factor receptor 1 (TNFR-1)-associated factor, is a novel early-acting gene that decreases markedly in expression during myogenic differentiation. RIP2 consists of three domains: an amino-terminal kinase domain, an intermediate domain, and a carboxy-terminal caspase activation and recruitment domain (CARD). In some cell types, RIP2 has been shown to be a potent inducer of apoptosis and an activator of NF-{kappa}B. To analyze the function of RIP2 during differentiation, we transduced C2C12 myoblasts with retroviral vectors to constitutively produce RIP2 at high levels. When cultured in growth medium, these cells did not show an enhanced rate of proliferation compared to controls. When switched to differentiation medium, however, they continued to proliferate, whereas control cells withdrew from the cell cycle, showed increased expression of differentiation markers such as myogenin, and began to differentiate into multinucleated myotubes. The complete RIP2 protein appeared to be necessary to inhibit myogenic differentiation, since two different deletion mutants lacking either the amino-terminal kinase domain or the carboxy-terminal CARD had no effect. A mutant deficient in kinase activity, however, had effects similar to wild-type RIP2, indicating that phosphorylation was not essential to the function of RIP2. Furthermore, RIP proteins appeared to be important during myogenic differentiation in vivo, as we detected a marked decrease in expression of the RIP2 homolog RIP in several muscle tissues of the dystrophic mdx mouse, a model for continuous muscle degeneration and regeneration. We conclude that RIP proteins can act independently of TNFR-1 stimulation by ligand to modulate downstream signaling pathways, such as activation of NF-{kappa}B. These results implicate RIP2 in a previously unrecognized role: a checkpoint for myogenic proliferation and differentiation.

* Corresponding author. Mailing address: Baxter Laboratory for Genetic Pharmacology, Stanford University Medical Center, 269 Campus Dr., CCSR 4215a, Stanford, CA 94305-5175. Phone: (650) 723-6209. Fax: (650) 736-0080. E-mail: hblau{at}stanford.edu.

Molecular and Cellular Biology, August 2002, p. 5879-5886, Vol. 22, No. 16
0022-538X/02/$04.00+0     DOI: 10.1128/MCB.22.16.5879-5886.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kim, C.-H., Neiswender, H., Baik, E. J., Xiong, W. C., Mei, L. (2008). {beta}-Catenin Interacts with MyoD and Regulates Its Transcription Activity. Mol. Cell. Biol. 28: 2941-2951 [Abstract] [Full Text]  
  • Luan, Y., Yu, X.-P., Yang, N., Frenkel, S., Chen, L., Liu, C.-j. (2008). p204 Protein Overcomes the Inhibition of Core Binding Factor {alpha}-1-mediated Osteogenic Differentiation by Id Helix-Loop-Helix Proteins. Mol. Biol. Cell 19: 2113-2126 [Abstract] [Full Text]  
  • Bakkar, N., Wang, J., Ladner, K. J., Wang, H., Dahlman, J. M., Carathers, M., Acharyya, S., Rudnicki, M. A., Hollenbach, A. D., Guttridge, D. C. (2008). IKK/NF-{kappa}B regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. JCB 180: 787-802 [Abstract] [Full Text]  
  • Wang, H., Hertlein, E., Bakkar, N., Sun, H., Acharyya, S., Wang, J., Carathers, M., Davuluri, R., Guttridge, D. C. (2007). NF-{kappa}B Regulation of YY1 Inhibits Skeletal Myogenesis through Transcriptional Silencing of Myofibrillar Genes. Mol. Cell. Biol. 27: 4374-4387 [Abstract] [Full Text]  
  • Luan, Y., Yu, X.-P., Xu, K., Ding, B., Yu, J., Huang, Y., Yang, N., Lengyel, P., Di Cesare, P. E., Liu, C.-j. (2007). The Retinoblastoma Protein Is an Essential Mediator of Osteogenesis That Links the p204 Protein to the Cbfa1 Transcription Factor Thereby Increasing Its Activity. J. Biol. Chem. 282: 16860-16870 [Abstract] [Full Text]  
  • Liu, C.-j., Chang, E., Yu, J., Carlson, C. S., Prazak, L., Yu, X.-P., Ding, B., Lengyel, P., Cesare, P. E. D. (2005). The Interferon-inducible p204 Protein Acts as a Transcriptional Coactivator of Cbfa1 and Enhances Osteoblast Differentiation. J. Biol. Chem. 280: 2788-2796 [Abstract] [Full Text]  
  • LANGEN, R. C. J., VAN DER VELDEN, J. L. J., SCHOLS, A. M. W. J., KELDERS, M. C. J. M., WOUTERS, E. F. M., JANSSEN-HEININGER, Y. M. W. (2004). Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J. 18: 227-237 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»